FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.
What happened
FDA inspected Indoco Remedies' drug manufacturing facility in Vasco Da Gama, Goa, India, from July 16 to 26, 2024. FDA found unreliable microbiological testing, inadequate airflow studies and unsuitable aseptic equipment conditions, plus deficient complaint investigations and unreviewed chromatography audit-trail messages. FDA said similar violations were cited in a February 2023 inspection.
What FDA found
The company lacked adequate controls to ensure microbiological test results were reliable, with particles on plates and filters and inconsistent media plate contact.
21 CFR 211.160(a)The company did not establish and follow adequate written procedures to prevent microbial contamination of sterile drugs, and airflow smoke studies were inadequate and repeated.
21 CFR 211.113(b)The company did not maintain equipment used to control aseptic conditions; FDA observed rough metal surfaces, protruding items, and exposed wires in ISO 5 areas.
21 CFR 211.42(c)(10)(vi)The company's investigations into complaints about blocked dispensing tips and missing or empty units were not scientifically sound.
21 CFR 211.192The quality unit did not ensure review of chromatography software warning and error messages or all audit-trail data.
21 CFR 211.22(a) and 211.22(d)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions and a schedule for any delays. FDA also recommends engaging a qualified Current Good Manufacturing Practice (CGMP) consultant.
Who should pay attention
- companies that rely on Indoco as a contract manufacturer
- brands and distributors selling Indoco-made finished drug products
- quality teams overseeing supplier qualification and complaint investigations
This is a summary. Read the original letter on fda.gov.